Saphnelo Injection, Solution
Product Images NDC 0310-3080

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Saphnelo (NDC 0310-3080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure_1 (Figure 1)

A line graph depicting the proportion of BICLA responders over time (in weeks) comparing anifrolumab 300 mg (N=180) and placebo (N=182). The y-axis shows the proportion of responders with standard error bars, increasing from 0 to 100%. The x-axis shows time points from 4 to 52 weeks. Two lines represent the treatments: a higher response proportion for anifrolumab and a lower, relatively stable response for placebo. A note below indicates that the same patients may not have responded at each time point.*

FDA Label Image

Single Dose Vial Carton Sales 300mg2ml

Packaging label for Saphnelo (anifrolumab-fnia) Injection, 300 mg/2 mL (150 mg/mL), a subcutaneous injection solution. The label indicates it is for intravenous infusion after dilution, must be refrigerated between 2°C to 8°C, and should be kept in the original carton to protect from light. The labeler is AstraZeneca Pharmaceuticals LP. The package contains 1 single-dose vial.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.